autologous anti-dll3 car-t cells lb2102
Generic: Autologous Anti-DLL3 CAR-T Cells LB2102
autologous anti-dll3 car-t cells lb2102: 1 clinical trial tracked.
autologous anti-dll3 car-t cells lb2102 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about autologous anti-dll3 car-t cells lb2102, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Primary endpoint: To characterize the safety and tolerability of LB2102 and determine recommended dose for expansion (RDE)
Interventionalopen41 targetStarted 2023-07Completion 2027-124 sites · United StatesLegend Biotech USA Inc